Search
Search Results
##search.searchResults.foundPlural##
-
PATHOGENESIS OF MALARIA IN TISSUES AND BLOOD
4737PDF: 2022HTML: 18185 -
THE BIOLOGY OF MYCOBACTERIUM TUBERCULOSIS INFECTION.
10944PDF: 6559HTML: 21962 -
INFECTIONS AND FOLLICULAR LYMPHOMA: IS THERE A LINK?
3401PDF: 1101HTML: 2441 -
-
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
3122PDF: 930HTML: 6619Untitled: 277Untitled: 236Untitled: 251Untitled: 261 -
POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: ROLE OF VIRAL INFECTION, GENETIC LESIONS AND ANTIGEN STIMULATION IN THE PATHOGENESIS OF THE DISEASE
1432PDF: 496HTML: 18632Figure 1: 201Figure 2: 185Figure 3: 197Figure 4: 230Figure 5: 205 -
PATHOGENESIS AND TREATMENT OF THROMBOHEMORRHAGIC DIATHESIS IN ACUTE PROMYELOCYTIC LEUKEMIA
1964PDF: 877HTML: 10362Figures 1,2,3: 246 -
THE ROLE OF INFECTION IN THE PATHOGENESIS OF VASO-OCCLUSIVE CRISIS IN PATIENTS WITH SICKLE CELL DISEASE.
5471PDF: 1398HTML: 2879Cover letter: 243 -
SICKLE CELL DISEASE AND VENOUS THROMBOEMBOLISM
2374PDF: 987HTML: 2327 -
BONE MARROW MICROENVIRONMENT INVOLVEMENT IN T-MN: FOCUS ON MESENCHYMAL STEM CELLS MESENCHYMAL STEM CELL IN T-MN
1982PDF: 1070HTML: 252 -
CURRENT KNOWLEDGE ON HIV-ASSOCIATED PLASMABLASTIC LYMPHOMA
2717PDF: 1697HTML: 2455Table1: 235 -
ROLE OF CYTOKINES AS MOLECULAR MARKER OF DENGUE SEVERITY
3330PDF: 1241HTML: 508 -
THE GUT MICROBIOTA AND IMMUNE SYSTEM RELATIONSHIP IN HUMAN GRAFT-VERSUS-HOST DISEASE
6495PDF: 2225HTML: 14161Untitled: 241figure: 223 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2695PDF: 863HTML: 5383 -
-
-
LYMPHOPROLIFERATIVE SYNDROMES ASSOCIATED WITH HUMAN HERPESVIRUS-6A AND HUMAN HERPESVIRUS-6B
3893PDF: 1672HTML: 873Figures . Eliassian: 273 -
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3752PDF: 2620HTML: 1661 -
-
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1540PDF: 993HTML: 259 -
Routine inflammatory markers are elevated in myelodysplastic syndromes at presentation Inflammatory marker elevation in MDS
989PDF: 735HTML: 266 -
NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL
2639PDF: 895HTML: 9065Efremov 1: 269Efremov 2: 237 -
IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS
3219PDF: 945HTML: 7312Kost Fig1: 225Kost Fig 2: 212Kost Fig3: 226Kost Fig 4: 238Kost Fig5: 233Kost fig 6: 216 -
HHVs AND LYMPHOPROLIFERATIVE DISORDERS
1512PDF: 876HTML: 3144 -
LYMPHOCYTES IN PATIENTS WITH CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1 EXPRESSION AND A PREVAILING TH2 IMMUNE RESPONSE. EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1
3040PDF: 1159HTML: 133 -
EVALUATION OF THE PLASMA MICRO RNA EXPRESSION LEVELS IN SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
1485PDF: 741HTML: 1190Untitled: 217Untitled: 181Untitled: 168Untitled: 187Untitled: 201 -
NEW THERAPEUTIC OPTIONS FOR THE TREATMENT OF SICKLE CELL DISEASE Guest Editor: Raffaella Origa
7133PDF: 3791HTML: 838 -
THE PROTHROMBOTIC STATE ASSOCIATED WITH SARS-COV-2 INFECTION: PATHOPHYSIOLOGICAL ASPECTS COVID and Thrombosis
2428PDF: 869HTML: 484 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1703PDF: 1123HTML: 492 -
RECENT ADVANCES IN THE 5Q- SYNDROME
3041PDF: 1919HTML: 3826Pellagatti Fig 1: 262Pellagatti Fig. 2: 249 -
PATHOBIOLOGY OF HODGKIN LYMPHOMA
3392PDF: 1547HTML: 5972Fig1-Ag-Pil: 280Ag-Pil Fig.2: 279 -
-
EBV-RELATED LYMPHOPROLIFERATIVE DISEASES: A REVIEW IN LIGHT OF NEW CLASSIFICATIONS EBV-RELATED LYMPHOPROLIFERATIVE DISEASES
4652PDF: 1803HTML: 1294 -
PEDIATRIC MASTOCYTOSIS: AN UPDATE Chldren' Mastocytosis
2042HTML: 1681PDF: 1184 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2370PDF: 1873HTML: 929 -
VASCULAR ENDOTHELIAL GROWTH FACTOR IN CHILDREN WITH THALASSEMIA MAJOR PDF
1404PDF: 921HTML: 1136Figure 1 the correlation between frequency of blood transfusion and serum vascular endothelial growth factor (VEGF).: 222







